The preceding paper (1) describes the changes which were found in the glycolytic intermediates of the human erythrocyte during 8 weeks' storage of blood at 40 C in acid citrate dextrose (ACD) supplemented with the nucleoside, inosine.
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Previous investigations had demonstrated that nucleosides not only were able to maintain a higher level of erythrocyte organic phosphate during storage but also that they could bring about a considerable resynthesis of organic from inorganic phosphate if added to the blood after several days of storage and then incubated for a few minutes at 370 C (2-4).
It was of interest, therefore, to extend our findings to a more detailed study of the nature of the phosphate compounds formed in the erythrocyte when nucleoside was added late in storage and to compare the results with those just described where inosine was present from the outset. In the experiments to be reported inosine was added to aliquots of human blood stored at 40 C in ACD: 1 ) after 3 weeks followed by another week at 40 C, and 2) after 4 weeks followed by 1 or 3 hours of incubation at 370 C. The phosphate compounds of the erythrocytes are compared with control samples kept for 4 weeks in ACD alone. It was considered worthwhile at this time to bring together available information on the metabolism of the stored red cell and to offer a tentative scheme to explain the events leading to loss of viability.
METHODS
Blood from a normal donor was drawn by gravity into ACD (NIH formula B) and stored at 40 C. After 21 days of storage, 100 ml of the ACD blood mixture was removed aseptically and to this was added inosine (4 mg per ml of blood) which had been autoclaved in normal saline in a concentration of 40 mg per ml. This sample * Supported by the US Army Medical Research and Development Command, Office of the Surgeon General, and by the National Heart Institute.
of blood was stored at 4°C for another 7 days. After 28 days of storage the remaining ACD blood was divided into three portions; one served as a control and to the other two the inosine solution was added to give a concentration of 4 mg (15 pmoles) per ml of original blood.
The aliquots treated with inosine were incubated for 1 and 3 hours at 370 C. Trichloroacetic acid extracts of the four samples were prepared, the metabolic intermediates were separated on columns of ion-exchange resin, and the compounds were analyzed as described in the preceding paper (1) .
RESULTS
The phosphate compounds of the stored red cells were first isolated by column chromatography on Dowex-1 resin by chloride eluants, as shown in Figure 1 . The 0.02 N HO elution section was rechromatographed by elution with ammonium formate buffer in order to separate the inosinic acid and adenosine diphosphate (ADP; Figure  2 ). Formate rechromatography was also carried out on the combined 0.003 and 0.01 N HCl elution sections to obtain better resolution of the sugar monophosphates ( Figure 3) . The results are summarized in Figure 4 , which for comparison includes data from the zero-day control and 4-week inosine experiments from the previous study (1) .
We would like to focus attention first on adenosine triphosphate (ATP) whose concentration may prove to be the most critical factor in the survival of the cell. Several points are of interest. When inosine was present from the outset of storage there was little increase of ATP over that found in ACD alone, whereas much higher levels were found when the nucleoside was added later. The stored cells which were exposed to inosine during the fourth week at 40 C had an ATP concentration as high as in the initial blood, and it was only slightly lower in the-3-hour 370 C incubation. It (10) for discussion of this concept]. However, during the steady state of normal metabolism in the human erythrocyte, significant participation of this cycle can be ruled out from the P32-labeling data which are consistent with a process that transfers most of the phosphorus from the carboxyl group of 1,3-diphosphoglycerate to ADP, to give 3-monophosphoglycerate which is then converted through the phosphoglycericmutase reaction to 2-monophosphoglycerate and so on (11) . Although the cycle does not appear to be operating under normal conditions, it can explain some of the changes observed during storage. Grisolia ( 12) has confirmed and extended these findings of Rapoport and co-workers, showing that 3-monophosphoglycerate accelerates the conversion of 1,3-diphosphoglycerate to 2,3-diphosphoglycerate and inhibits the 2,3-diphosphoglycerate phosphatase. With this background the events taking place during storage can be reconstructed as follows. When 1,3-diphosphoglycerate and 3-monophosphoglycerate are no longer being produced because of a defect higher in the metabolic path, the 3-monophosphoglycerate inhibition of the phosphatase is released, and the 2,3-diphosphoglycerate disappears rapidly by hydrolysis to monophosphoglycerate which can be converted to lactate. When 1,3-diphosphoglycerate and 3-monophosphoglycerate are replenished from the catabolism of ino-sine, the 3-monophosphoglycerate blocks the phosphatase split of 2,3-diphosphoglycerate and stimulates its formation from 1,3-diphosphoglycerate. The 3-monophosphoglycerate kinase and the diphosphoglycerate mutase continue as competing reactions until the level of the 2,3-diphosphoglycerate is raised high enough to inhibit its further synthesis, at which time the kinase takes over as the primary reaction for the conversion of 1,3-diphosphoglycerate to 3-monophosphoglycerate.
Not only ATP but total adenine nucleotide was reduced in the erythrocyte during storage in ACD and could be regenerated in the presence of inosine. It seems of special importance to try to understand the mechanisms involved. The socalled de novo synthesis of purine nucleotide from small units such as glycine and formate has been intensively investigated in recent years, and a rather complex path has emerged which seems to be widely distributed in nature (13) . Human or rabbit erythrocytes lack the capacity to carry out this over-all de novo synthesis of purine nucleotide (14) . However, another important pathway for the biosynthesis of purine nucleotide is by the reaction of preformed purine with phosphoribosylpyrophosphate to give the nucleoside, 5' phosphate (15) . It has been demonstrated that the intact human or rabbit erythrocyte can incorporate C14-labeled adenine or hypoxanthine into adenylate (16, 17) presumably by a reaction with phosphoribosylpyrophosphate. Moreover, extracts of human erythrocytes have been found to make phosphoribosylpyrophosphate and to react it with adenine or hypoxanthine to give nucleotide (18) . From these observations it seems probable that the first step in the net synthesis of adenylate from inosine seen in the stored cells is the reaction of hypoxanthine (from inosine) with phosphoribosylpyrophosphate to give inosinic acid. Apparently the major route for the conversion of inosinate to adenylate in most kinds of cells is' by a reaction with aspartate to give adenylosuccinate which splits to adenylate (19) . This reaction has not been examined in the erythrocyte. One other possibility for the synthesis of nucleotide by the erythrocyte must be kept in mind and that is a direct phosphorylation of nucleoside, although this reaction is not generally thought to comprise an important fraction of purine nucleotide formation in the animal (20) .
Instead of speaking of ATP alone, it is more instructive to consider the combined AMP-ADP-ATP pool and divide it into two parts: 1) the fraction in the form of high energy phosphate, and 2) the content of total adenylate. In the normal cell the fraction as ATP is very high, and the amount of high energy phosphate entering the pool from the reactions of the glycolytic chain is balanced by the amount going out through phosphorylations of hexose and hexose phosphate and the action of ATPases. The total adenylbate is kept constant with a small but significant turnover of the AMP-unit during the life of the cell, as shown by Lowy, Ramot and London (16) . During storage in ACD both the high energy phosphate and the total adenylate decrease. As will be discussed later, we believe that a defect early in the glycolytic path decreases the amount of high energy phosphate coming into the adenylate pool. If we assume that the usual ATPase activities continue, then the ATP concentration will fall. Due to the presence of a potent adenylate kinase (21) (22) (23) , the ADP formed by the action of ATPase will be converted to AMP and ATP, and this process will continue until all of the adenylate is changed into AMP. However, we did not find AMP accumulating in the stored cells and must postulate that some mechanism is released which increases the rate of its breakdown above the normal. This could be a direct effect of increased concentration of AMP on the enzyme involved, or it might result from the disappearance of an inhibitor (for example, ATP). The first step in the degradation of the AMP is probably mediated by the enzyme 5'-nucleotidase (24) either before or after deamination (25) to inosinate, or perhaps both. We have seen that a small amount of inosinic acid accumulates during the storage. The products of the 5'-nucleotidase, adenosine (after conversion to inosine by a nucleoside deaminase) (26,-27) and inosine, would be split to hypoxanthine and ribose phosphate by nucleoside phosphorylase (28) (29) (30) . Several studies have shown that hypoxanthine is the principal endproduct of nucleotide decomposition in the erythrocyte (31) (32) (33) We know that there is a critical period during storage when the red cell which would have been removed rapidly from the circulation upon transfusion will survive if it has had a treatment with nucleoside. It is unlikely that nucleosides are present in the blood stream in amounts sufficient to continue to serve as the principal substrate for the erythrocyte, and it seems most probable that somehow the ability to use glucose is restored in the body. Assuming such a reversibility of the storage lesion to be the case, and that the phosphorylation of glucose is involved, what are possible contributing factors ? Protein denaturation can be ruled out, since as far as is known the mature erythrocyte cannot synthesize protein and so would not be able to make any new hexokinase enzyme after returning to the circulation. As mentioned, the hexokinase reaction is probably located in the surface area of the cell and so is vulnerable to influences which would cause loss to the storage medium of controlling cofactors for the enzyme-agents which could reasonably be regained in the more favorable environment of the circulation. It is also conceivable that reactions selectively localized in the cell membrane have a restricted orientation vis a vis the exterior and interior, distortion of which by the highly abnormal medium might lead to decreased enzyme activity, an inhibition which could be eliminated on return of the erythrocyte to the circulation.
In summary, a tentative scheme has been formulated to explain the storage lesion ( Figure 5 
SUMMARY
The effect of inosine on the phosphorylated metabolic intermediates of the human erythrocyte stored at 40 C in acid citrate dextrose preservative was determined after the addition of the nmcleoside: 1) after 3 weeks followed by another week at 40 C, and 2) after 4 weeks followed by 1 or 3 hours of incubation at 370 C. Inosine produced extensive resynthesis of some of the organic phosphates normally present in the fresh erythryocyte and led to important quantitative and qualitative changes in the normal pattern of metabolites. In the light of the results found here and reported elsewhere a scheme has been proposed to explain the biochemical events leading to a loss in viability of the stored erythrocyte.
